HK1110221A1 - Use of prodrugs for ocular intravitreous administration - Google Patents

Use of prodrugs for ocular intravitreous administration

Info

Publication number
HK1110221A1
HK1110221A1 HK08104540.9A HK08104540A HK1110221A1 HK 1110221 A1 HK1110221 A1 HK 1110221A1 HK 08104540 A HK08104540 A HK 08104540A HK 1110221 A1 HK1110221 A1 HK 1110221A1
Authority
HK
Hong Kong
Prior art keywords
ocular
prodrugs
intravitreous administration
intravitreous
administration
Prior art date
Application number
HK08104540.9A
Other languages
English (en)
Inventor
Laura Rabinovich-Guilatt
Gregory Lambert
Original Assignee
Novagali Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novagali Pharma Sa filed Critical Novagali Pharma Sa
Publication of HK1110221A1 publication Critical patent/HK1110221A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK08104540.9A 2006-06-01 2008-04-23 Use of prodrugs for ocular intravitreous administration HK1110221A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06290902A EP1864668B1 (en) 2006-06-01 2006-06-01 Use of prodrugs for ocular intravitreous administration
US11/444,349 US20070280902A1 (en) 2006-06-01 2006-06-01 Method for treating eye disease or conditions affecting the posterior segment of the eye
EP06290901.5A EP1864667B1 (en) 2006-06-01 2006-06-01 Use of prodrugs for ocular intravitreous administration
US11/444,337 US20070281914A1 (en) 2006-06-01 2006-06-01 Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye

Publications (1)

Publication Number Publication Date
HK1110221A1 true HK1110221A1 (en) 2008-07-11

Family

ID=39712456

Family Applications (2)

Application Number Title Priority Date Filing Date
HK08104425.9A HK1110219A1 (en) 2006-06-01 2008-04-21 Use of prodrugs for ocular intravitreous administration
HK08104540.9A HK1110221A1 (en) 2006-06-01 2008-04-23 Use of prodrugs for ocular intravitreous administration

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK08104425.9A HK1110219A1 (en) 2006-06-01 2008-04-21 Use of prodrugs for ocular intravitreous administration

Country Status (15)

Country Link
US (4) US20070281914A1 (xx)
EP (4) EP2319517B1 (xx)
JP (2) JP5284953B2 (xx)
KR (1) KR101408317B1 (xx)
CN (1) CN101553235B (xx)
AU (1) AU2007267079B2 (xx)
CA (1) CA2653902C (xx)
DK (2) DK1864668T3 (xx)
ES (1) ES2399976T3 (xx)
HK (2) HK1110219A1 (xx)
IL (1) IL195626A (xx)
PL (4) PL1864667T3 (xx)
PT (2) PT1864667E (xx)
SI (1) SI1864668T1 (xx)
WO (2) WO2007138113A1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1864667T3 (pl) 2006-06-01 2014-01-31 Santen Sas Zastosowanie proleków do podania do ciała szklistego oka
DK2214646T3 (da) * 2007-10-05 2021-10-04 Univ Wayne State Dendrimers for sustained release of compounds
EP2229174A1 (en) 2007-12-04 2010-09-22 Novagali Pharma S.A. Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
WO2009140246A2 (en) 2008-05-12 2009-11-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
UA116622C2 (uk) 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей
NZ628124A (en) * 2012-02-10 2016-06-24 Taiwan Liposome Co Ltd Pharmaceutical compositions to reduce complications of ocular steroid
KR102619458B1 (ko) 2017-06-16 2023-12-29 학교법인 도시샤 mTOR 인히비터를 포함하는, 눈의 증상, 장해 또는 질환을 치료 또는 예방하기 위한 의약 및 그 응용
CA3082121C (en) 2017-11-10 2023-01-24 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
CN111068071A (zh) * 2018-10-22 2020-04-28 武汉纽福斯生物科技有限公司 基因治疗Leber遗传学视神经病变
PL3871662T3 (pl) * 2020-02-25 2023-11-20 Labomed Pharmaceutical Company S.A. Doustne roztwory zawierające octan fludrokortyzonu
JP2023542435A (ja) 2020-09-16 2023-10-06 サンテン エスエーエス 硝子体内投与のための水中油型油エマルション

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS609726B2 (ja) 1980-05-15 1985-03-12 株式会社 ミドリ十字 ステロイド製剤
JPS5716818A (en) * 1981-04-25 1982-01-28 Green Cross Corp:The Steroid fatty emulsion
AU531588B2 (en) 1981-08-17 1983-09-01 Yoshitomi Pharmaceutical Industries, Ltd. Emulsifying water-insoluble steroid
AU604236B2 (en) * 1986-04-28 1990-12-13 Iolab, Inc. Intraocular dosage compositions and method of use
AU4201189A (en) 1988-08-26 1990-03-23 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
JPH05132498A (ja) * 1991-11-08 1993-05-28 Asahi Glass Co Ltd ステロイド誘導体およびその製剤
IL101241A (en) 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
CA2125060C (en) 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
DK0712389T3 (da) * 1993-08-02 2001-06-05 Commw Scient Ind Res Org Terapeutisk forbindelse - fedtsyrekonjugater
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
JP3410364B2 (ja) 1997-05-14 2003-05-26 千寿製薬株式会社 ジフルプレドナート含有組成物
US6114319A (en) 1997-05-14 2000-09-05 Senju Pharmaceutical Co., Ltd. Compositions containing difluprednate
IL121647A (en) * 1997-08-28 2001-07-24 Pharmateam Dev Ltd Pharmaceutical compositions for the treatment of ocular inflammation comprising dexamethasone palmitate
EP1020194A4 (en) 1997-10-01 2003-05-21 Wakamoto Pharma Co Ltd OIL / WATER EMULSION COMPILATIONS
JP2000212067A (ja) * 1999-01-19 2000-08-02 Towa Yakuhin Kk 薬物含有エマルジョン製剤
JP2005513097A (ja) 2001-11-01 2005-05-12 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム ドライアイ治療方法および組成物
EP1572216A1 (en) * 2002-12-20 2005-09-14 Control Delivery Systems, Inc. Steroid compositions for intraocular use
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
CA2539741A1 (en) * 2003-09-22 2005-03-31 Bionetworks Gmbh Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
DE602004022523D1 (de) * 2004-07-02 2009-09-24 Novagali Pharma Sa Verwendung von Emulsionen zur intra- und periocularen Injection
AU2005271700B2 (en) * 2004-07-12 2010-11-11 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
JP5682991B2 (ja) * 2004-10-01 2015-03-11 ラムズコア， インコーポレイテッド 便利に移植可能な徐放性薬物処方物
US20060094700A1 (en) * 2004-11-02 2006-05-04 Allergan, Inc. Heat sterilization of a steroid in the presence of phosphate
AU2005304034B2 (en) 2004-11-09 2012-02-16 Santen Sas Ophthalmic emulsions containing an immunosuppressive agent
CN1905012A (zh) 2005-07-31 2007-01-31 新科实业有限公司 具有微驱动器的磁头折片组合及其磁盘驱动装置
US8109884B2 (en) 2005-09-23 2012-02-07 Kitchener Clark Wilson Dynamic metabolism monitoring system
PL1864667T3 (pl) 2006-06-01 2014-01-31 Santen Sas Zastosowanie proleków do podania do ciała szklistego oka

Also Published As

Publication number Publication date
JP5455624B2 (ja) 2014-03-26
DK1864668T3 (da) 2013-03-04
JP2009538879A (ja) 2009-11-12
DK2319517T3 (da) 2013-12-09
KR20090031373A (ko) 2009-03-25
EP2322183B1 (en) 2014-10-22
JP5284953B2 (ja) 2013-09-11
PT1864667E (pt) 2013-11-18
ES2399976T3 (es) 2013-04-04
SI1864668T1 (sl) 2013-04-30
AU2007267079B2 (en) 2013-01-31
HK1110219A1 (en) 2008-07-11
CA2653902C (en) 2015-03-17
PL2322183T3 (pl) 2015-01-30
IL195626A0 (en) 2009-09-01
CA2653902A1 (en) 2007-12-06
US20070280995A1 (en) 2007-12-06
US8227452B2 (en) 2012-07-24
EP1864668A1 (en) 2007-12-12
CN101553235B (zh) 2012-12-05
KR101408317B1 (ko) 2014-06-17
US20070281913A1 (en) 2007-12-06
PT1864668E (pt) 2013-02-26
WO2007138114A1 (en) 2007-12-06
EP1864667A1 (en) 2007-12-12
JP2009538880A (ja) 2009-11-12
EP2322183A1 (en) 2011-05-18
CN101553235A (zh) 2009-10-07
PL1864668T3 (pl) 2013-04-30
US20070281914A1 (en) 2007-12-06
US20070280902A1 (en) 2007-12-06
EP2319517B1 (en) 2013-09-11
EP1864667B1 (en) 2013-09-04
EP1864668B1 (en) 2012-11-21
AU2007267079A1 (en) 2007-12-06
US9192567B2 (en) 2015-11-24
PL2319517T3 (pl) 2014-01-31
WO2007138113A1 (en) 2007-12-06
EP2319517A1 (en) 2011-05-11
PL1864667T3 (pl) 2014-01-31
IL195626A (en) 2017-05-29

Similar Documents

Publication Publication Date Title
HK1110221A1 (en) Use of prodrugs for ocular intravitreous administration
EP2963031A3 (en) Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
MX2007008848A (es) Metodos y composiciones para el tratamiento de desordenes oculares.
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
WO2007002390A3 (en) Compositions and methods for modulation of smn2 splicing
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
MX2010003667A (es) Compuestos alcoxi para el tratamiento de enfermedades.
EP2386299A3 (en) 1-Amino-Alkylcyclohexane derivatives for the treatment of cochlear tinnitus
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
EP3069612A3 (en) Dithiol compounds, derivatives, and uses therefor
SI1984357T1 (sl) Spojine 2,4-pirimidindiamina za zdravljenje ali preventivo avtoimunih bolezni
WO2007128802A3 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
ZA200801171B (en) 3, IIB-CIS-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
WO2009005794A3 (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
WO2009071690A3 (de) 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
WO2007135426A3 (en) Treatment of neurodegeneratives diseases
WO2011037837A3 (en) Vaginal vault suspension device and method
WO2011031518A3 (en) Femoral guide for acl repair having reduced profile for left/right knee configurations
WO2008105507A1 (ja) 脊髄損傷治療薬剤
EP1741430A4 (en) REMEDY FOR PSYCHO NEUROSIS DISEASES
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine
WO2007109174A3 (en) Compositions and methods for modulation of mcl-1 expression
WO2008011473A3 (en) Compositions and their uses directed to hbxip
CL2007003275A1 (es) Compuestos derivados de 4-imidazoles sustituidos; proceso de preparacion; medicamento; y uso para el tratamiento de depresion, trastornos de ansiedad, trastornos psicoticos, esquizofrenia, enfermedad de parkinson, migrana, entre otras.
WO2006083916A3 (en) Novel adenosine a3 receptor modulators

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220528